Posted by Michael Wonder on 24 Mar 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis of COVID-19
24 March 2022 - Recommendation based on Phase 3 PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months.
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union for the pre-exposure prophylaxis of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.
